<DOC>
	<DOCNO>NCT00298623</DOCNO>
	<brief_summary>The primary objective trial ass efficacy XP13512 take daily compare placebo treatment patient suffer Restless Legs Syndrome ( RLS ) .</brief_summary>
	<brief_title>XP13512 ( GSK1838262 ) Versus Placebo Patients With Restless Legs Syndrome .</brief_title>
	<detailed_description />
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Psychomotor Agitation</mesh_term>
	<mesh_term>Restless Legs Syndrome</mesh_term>
	<criteria>Patients primary RLS , base International RLS Study Group Diagnostic Criteria . History RLS symptoms least 15 night prior month , treatment , frequency symptom treatment start ; Documented RLS symptoms least 4 7 consecutive evenings/nights Baseline study period ; Total RLS severity score 15 great International Restless Legs Syndrome Study Group Rating Scale ( IRLS rating scale ) Visit 1 Visit 2 ; Discontinuation dopamine agonist and/or gabapentin least 2 week prior Baseline ; Discontinuation treatment RLS ( e.g. , opioids , benzodiazepine ) least 2 week prior Baseline ; If female childbearing potential , subject must agree use clinically accept birth control completion study ; Body Mass Index 34 ; Estimated creatinine clearance least 60 mL/min ; A sleep disorder ( e.g. , sleep apnea ) may significantly affect assessment RLS ; Neurologic disease movement disorder ( e.g. , diabetic neuropathy , Parkinson 's Disease , Multiple Sclerosis , dyskinesia , dystonias ) ; Abnormal laboratory result , electrocardiogram ( ECG ) physical finding ; Pregnant lactate woman ; Women childbearing potential practicing acceptable method birth control .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2011</verification_date>
</DOC>